METHODS & MATERIALS:
Bioresorbable scaffolds (microporous membranes and 3-D sponges) were produced from poly(L/DL-lactide) 80/20% with a molecular weight of 200 kD (PURAC Biochem; Gorinchem, The Netherlands). The membranes had interconnected open pores with an average size of 50 to 70 µm. The 3-D sponges had the average pore size in the range of 450-700 µm, and the pore-to-volume ratio in the scaffold 94%.
Ten patients with bone defect of sizes up to 6 cm due to various causes including benign tumour, osteomyelitis & fractures were treated with resorbable polylactide scaffold impregnated with marrow blood which contains stromal cells. In cases with infection, antibiotics was also loaded into the scaffold and in this situation, the scaffold also served as a drug delivery device. The patients have been assessed regularly with X -rays and clinical symptoms.
RESULTS:
Serial X -ray evaluation and clinical evaluation revealed presence of bone regeneration. The limbs enjoyed satisfactory function and there was minimal donor site morbidity and major surgery can be avoided.
DISCUSSION AND CONCLUSIONS:
Segmental bone defects in s elected clinical cases were treated using bioresorbable porous polymeric scaffolds impregnated with autogenous marrow blood. Such cases would be treated otherwise by conventional techniques.
Vascularized bone transfer has limited supply and involves a major operation. There is always a chance of vascular complication and there is donor site morbidity. There is a limitation in bone defect size that can be lengthened using distraction osteogenesis, and in addition, this procedure requires a prolonged placement of an external fixation. There is a high chance of traction injury to nerve and other soft tissues.
Massive allograft requires a prolonged period, in terms of decades, for complete creep substitution. There is also a high incidence of disease transmission and infection.
Therefore there is a constant demand for bone substitute which can bridge long segmental defect effectively with minimal morbidity and can heal in reasonable time frame. The affected limb can be rehabilitated and bear weight for functional restoration as early as possible. If such a substitute is radiolucent this would be an additional advantage for a radiographic assessment of bone healing.
Such a new bone substitute can be for example produced from bioresorbable polymers and/or composites consisting of bioresorbale polymers and calcium phosphate ceramics which would add and osteoconductive component to the implant. Impregnation of such bone substitutes with autogenous bone marrow or marrow blood would also make osteoinductive. The early promising results of this study show that such an approach to new bone substitutes is feasible.
